Table 2.
Time course of hypercalcaemia in patient randomised to vitamin D supplements
| Weeks* | Dietary calcium (mg/day) | Serum calcium† (mmol/L) | Serum phosphate (mmol/L) | Serum creatinine (µmol/L) | 24 h Urine calcium (mmol/day) | 25OHD (nmol/L) | 1,25OHD (pmol/L) | PTH (pmol/L) |
|---|---|---|---|---|---|---|---|---|
| 0 | 460 | 2.26 | 1.24 | 76 | 4.2 | 18 | 77 | 2.3 |
| 2 | 2.36 | 1.28 | 74 | |||||
| 4 | 2.48 | 1.57 | 83 | 14.4 | 69 | 218 | 0.9 | |
| 6 | 2.88 | 1.55 | 112 | |||||
| 7 | 2.87 | 1.31 | 125 | |||||
| 8 | 2.65 | 1.45 | 124 | |||||
| 12 | 2.46 | 1.23 | 93 | |||||
| 16 | 2.22 | 1.14 | 75 | |||||
| 26 | 2.28 | 1.04 | 71 | 31 | 81 | 2.2 | ||
| 52 | 2.27 | 1.11 | 78 | 6.7 | 41 | 77 | 2.1 |
*Study treatment was stopped at 6 weeks when hypercalcaemia was recognised. The last dose was taken at week 5, and five 50 000 IU doses of cholecalciferol were taken over 5 weeks.
†Albumin-adjusted serum calcium.
1,25OHD, 1,25-dihydroxyvitamin D; 25OHD, 25-hydroxyvitamin D; PTH, parathyroid hormone.